Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Assoc. Prof. Folkert Asselbergs,
View the Slides from this session in ESC Congress 365
This symposium clearly illustrated that pharmacogenetics is not an obscure hobby of basic scientists, but will be applicable in clinical practice in the near future.
Dr. Munir Pirmohamed (Liverpool, GB) and Dr Anke Hilse Maitland-van der Zee (Utrecht, NL) discussed whether dosing of oral anticoagulants needs to be guided by pharmacogenetics. The jury is still out, but a genotype-guided loading dose of anticoagulants seems beneficial, especially when genotyping costs keep decreasing.
Another clinical application is the genetic background of statin side effects as discussed by Dr. Mikko Niemi from (Helsinki, FL). Several genetic factors have been identified that increases the toxicity of certain statins, one variant increases the risk more than threefold. Dr. Niemi proposed creating a guideline for statin prescription based on genotype information. Availability of genetic information in patients using statins would help to prevent severe drug reactions.
Finally, Dr Elijah Behr ( London, GB) updated the audience regarding genetics of QT prolongation and torsades de pointes by drug use. Some interesting variants, such as NOS1AP were identified but large sample sizes are needed to fully understand the underlying genetic background responsible for QT prolongation.
In conclusion, pharmacogenetics is an exciting fast-moving field that cannot be ignored anymore by the practicing clinician. It will only be matter of time before patients provide you with their genetic data to interpret.
Pharmacogenetics: ready for clinical practice?, Science in Practice from early detection to guided treatment
© 2016 European Society of Cardiology. All rights reserved